Overview

A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery

Status:
NOT_YET_RECRUITING

Trial end date:
2031-07-01

Target enrollment:

Participant gender:

Summary

Tuberculosis is a leading global cause of morbidity and mortality. Even if cured, a majority patients are left with bronchiectasis and fibrosis, permanent conditions that impair lung function. Large cohort studies have confirmed that even modest loss of lung function is associated with excess mortality risk. This study will examine if two treatments, metformin and N-acetylcysteine (NAC), can promote the recovery of lung function in TB if given together with standard TB treatment. There currently are no drugs approved for this indication.

Phase:

PHASE3

Details

Lead Sponsor:

Open Source Pharma Foundation

Collaborator:

National Institute for Research in Tuberculosis, Chennai, India

Treatments:

Acetylcysteine
Metformin
Therapeutics